This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from increase in RAYALDEE prescriptions.
OPKO Health (OPK) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) first-quarter performance is likely to reflect solid performance from Products and RAYALDEE.
Will OPKO Health (OPK) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain OPKO Health in Your Portfolio
by Zacks Equity Research
Investor confidence remains high in OPKO Health's (OPK) stock, thanks to solid prospects.
Do Options Traders Know Something About OPKO Health (OPK) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.
Why Is OPKO Health (OPK) Down 4.2% Since Last Earnings Report?
by Zacks Equity Research
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OPKO's BioReference Laboratories Widens COVID-19 Testing (Revised)
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
OPKO's BioReference Laboratories Offers COVID-19 Testing (Revised)
by Zacks Equity Research
OPKO's (OPK) BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties in New Jersey.
OPKO's BioReference Laboratories Widens COVID-19 Testing
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
OPKO's BioReference Laboratories Offers COVID-19 Testing
by Zacks Equity Research
OPKO's (OPK) BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties in New Jersey.
The Zacks Analyst Blog Highlights: Co-Diagnostics, GenMark Diagnostics, OPKO Health and Inovio Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Co-Diagnostics, GenMark Diagnostics, OPKO Health and Inovio Pharmaceuticals
4 Stocks to Gain the Most From the Coronavirus Outbreak
by Nilanjan Banerjee
It is worthwhile to keep an eye on stocks of companies that are engaged in the prevention, diagnosis and treatment of the disease.
Company News for Mar 9, 2020
by Zacks Equity Research
Companies In The News Are: OPK, AOBC, DXPE, TGNA
Implied Volatility Surging for OPKO Health (OPK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.
Here's Why You Should Hold on to OPKO Health Stock for Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
OPKO Health (OPK) Q4 Loss Narrower Than Estimates, Sales Up
by Zacks Equity Research
OPKO (OPK) gains from increase in RAYALDEE prescriptions.
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 25.00% and 3.48%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to OPKO Health Stock for Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
Why Is OPKO Health (OPK) Up 10.8% Since Last Earnings Report?
by Zacks Equity Research
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to OPKO Health (OPK) Stock Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
OPKO Health (OPK) Q3 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.
OPKO Health (OPK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -22.22% and 1.92%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: OPKO Health (OPK) Q3 Earnings Expected to Decline
by Zacks Equity Research
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OPKO Health Enters Oversold Territory
by Zacks Equity Research
OPKO Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.